KSHV latent protein LANA2 inhibits sumo2 modification of p53

References

• Collot-Teixeira S, Bass J, Denis F, Ranger-Rogez S. Human tumor suppressor p53 and DNA viruses. Rev Med Virol 2004; 14:301-19; PMID:15334538; http://dx.doi.org/10.1002/rmv.431
   PubMed Web of Science ®Google Scholar
• Jayaraman L, Prives C. Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 1999; 55:76-87; PMID:10065153; http://dx.doi.org/10.1007/s000180050271
   PubMed Web of Science ®Google Scholar
• Baresova P, Musilova J, Pitha PM, Lubyova B. p53 Tumor Suppressor Protein Stability and Transcriptional Activity Are Targeted by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interferon Regulatory Factor 3. Mol Cell Biol 2014; 34:386-99; PMID:24248600; http://dx.doi.org/10.1128/MCB.01011-13
   PubMed Web of Science ®Google Scholar
• Chudasama P, Konrad A, Jochmann R, Lausen B, Holz P, Naschberger E, et al. Structural proteins of Kaposi's sarcoma-associated herpesvirus antagonize p53-mediated apoptosis. Oncogene 2014; PMID:24469037
   PubMed Web of Science ®Google Scholar
• Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402:889-94; PMID:10622254
   PubMed Web of Science ®Google Scholar
• Gwack Y, Hwang S, Byun H, Lim C, Kim JW, Choi EJ, et al. Kaposi's sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol 2001; 75:6245-8; PMID:11390631; http://dx.doi.org/10.1128/JVI.75.13.6245-6248.2001
   PubMed Web of Science ®Google Scholar
• Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 2009; 83:6739-47; PMID:19369353; http://dx.doi.org/10.1128/JVI.02353-08
   PubMed Web of Science ®Google Scholar
• Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001; 75:429-38; PMID:11119611; http://dx.doi.org/10.1128/JVI.75.1.429-438.2001
   PubMed Web of Science ®Google Scholar
• Marcos-Villar L, Gallego P, Munoz-Fontela C, de la Cruz-Herrera CF, Campagna M, Gonzalez D, Lopitz-Otsoa F, Rodríguez MS, Rivas C. Kaposi's sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation. Oncogene 2014; 33:495-503; PMID:23318443; http://dx.doi.org/10.1038/onc.2012.603
   PubMed Web of Science ®Google Scholar
• Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Munoz-Fontela C, Gonzalez-Santamaria J, Campagna M, Shou-Jiang G, Rodriguez MS, Rivas C. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 2009; 83:8849-58; PMID:19553342; http://dx.doi.org/10.1128/JVI.00339-09
   PubMed Web of Science ®Google Scholar
• Marcos-Villar L, Campagna M, Lopitz-Otsoa F, Gallego P, Gonzalez-Santamaria J, Gonzalez D, Rodriguez MS, Rivas C. Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Gen Virol 2011; 92:188-94; PMID:20881090; http://dx.doi.org/10.1099/vir.0.024984-0
   PubMed Web of Science ®Google Scholar
• Li T, Santockyte R, Shen RF, Tekle E, Wang G, Yang DC, Chock PB. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J Biol Chem 2006; 281:36221-7; PMID:17012228; http://dx.doi.org/10.1074/jbc.M608236200
   PubMed Web of Science ®Google Scholar
• Marcos-Villar L, Perez-Giron JV, Vilas JM, Soto A, de la Cruz-Hererra CF, Lang V, Collado M, Vidal A, Rodríguez MS, Muñoz-Fontela C, et al. SUMOylation of p53 mediates interferon activities. Cell Cycle 2013; 12:2809-16; PMID:23966171; http://dx.doi.org/10.4161/cc.25868
   PubMed Web of Science ®Google Scholar
• Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. Embo J 1999; 18:6462-71; PMID:10562558; http://dx.doi.org/10.1093/emboj/18.22.6462
   PubMed Web of Science ®Google Scholar
• Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 2000; 275:13321-9; PMID:10788439; http://dx.doi.org/10.1074/jbc.275.18.13321
   PubMed Web of Science ®Google Scholar
• Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, Grosschedl R, Dejean A. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 2006; 22:783-94; PMID:16793547; http://dx.doi.org/10.1016/j.molcel.2006.05.016
   PubMed Web of Science ®Google Scholar
• Yates KE, Korbel GA, Shtutman M, Roninson IB, DiMaio D. Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell 2008; 7:609-21; PMID:18616636; http://dx.doi.org/10.1111/j.1474-9726.2008.00411.x
   PubMed Web of Science ®Google Scholar
• Wies E, Mori Y, Hahn A, Kremmer E, Sturzl M, Fleckenstein B, Neipel F. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008; 111:320-7; PMID:17890449; http://dx.doi.org/10.1182/blood-2007-05-092288
   PubMed Web of Science ®Google Scholar
• Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 1998; 2:233-9; PMID:9734360; http://dx.doi.org/10.1016/S1097-2765(00)80133-1
   PubMed Web of Science ®Google Scholar
• Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics 2006; 5:2298-310; PMID:17000644; http://dx.doi.org/10.1074/mcp.M600212-MCP200
   PubMed Web of Science ®Google Scholar
• Campagna M, Herranz D, Garcia MA, Marcos-Villar L, Gonzalez-Santamaria J, Gallego P, Gutierrez S, Collado M, Serrano M, Esteban M, Rivas C. SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ 2011; 18:72-9; PMID:20577263; http://dx.doi.org/10.1038/cdd.2010.77
   PubMed Web of Science ®Google Scholar
• Chang PC, Li M. Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor. J Virol 2008; 82:278-90; PMID:17942552; http://dx.doi.org/10.1128/JVI.01552-07
   PubMed Web of Science ®Google Scholar
• Curreli F, Friedman-Kien AE, Flore O. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 2005; 115:642-52; PMID:15765147; http://dx.doi.org/10.1172/JCI200523334
   PubMed Web of Science ®Google Scholar
• Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2006; 2:e116.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Li M, Zarycki J, Jung JU. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol 2001; 75:7572-82; PMID:11462029; http://dx.doi.org/10.1128/JVI.75.16.7572-7582.2001
   PubMed Web of Science ®Google Scholar
• Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF, Jung JU. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 2006; 80:2257-66; PMID:16474133; http://dx.doi.org/10.1128/JVI.80.5.2257-2266.2006
   PubMed Web of Science ®Google Scholar
• Feng P, Scott CW, Cho NH, Nakamura H, Chung YH, Monteiro MJ, Jung JU. Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation. Mol Cell Biol 2004; 24:3938-48; PMID:15082787; http://dx.doi.org/10.1128/MCB.24.9.3938-3948.2004
   PubMed Web of Science ®Google Scholar
• Chang PC, Izumiya Y, Wu CY, Fitzgerald LD, Campbell M, Ellison TJ, Lam KS, Luciw PA, Kung HJ. Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J Biol Chem 2010; 285:5266-73; PMID:20034935; http://dx.doi.org/10.1074/jbc.M109.088088
   PubMed Web of Science ®Google Scholar